Advertisement

p53 as a Prognostic and Predictive Indicator

  • Daniela Kandioler
  • Raimund Jakesz
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Cancer is a disease of genes, and the p53 gene appears to be the most frequently mutated gene associated with human cancer. p53 is crucially involved in numerous central pathways determining the life and death of a cell. The information about the functional status of p53 has been considered to be extremely important for estimation of prognosis and the need of further treatment as well as for prediction of response and the selection of the optimal therapy. The aim of this chapter is to evaluate why one of the most promising and most intensively studied markers is not recommended for routine clinical use to date. The pitfalls of the p53 analysis and the challenges of well-designed p53 studies are elucidated and the need of carefully planned studies using an optimal p53 analysis method is pointed out.

Key Words

p53 biological marker prognostic predictive p53 sequencing p53 immunohistochemistry p53 study design 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000;11:647–663.PubMedCrossRefGoogle Scholar
  2. 2.
    Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966–978.PubMedGoogle Scholar
  3. 3.
    Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 1999;18:7637–7643.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris CC. 1995 Deichmann Lecture-p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol Lett 1995;82–83:1–7.Google Scholar
  5. 5.
    Dublin EA, Miles DW, Rubens RD, Smith P, Barnes DM. p53 immunohistochemi-cal staining and survival after adjuvant chemotherapy for breast cancer. Int J Cancer 1997;74:605–608.PubMedCrossRefGoogle Scholar
  6. 6.
    Kandioler D, Zwrtek R, Ludwig C, et al. TP53 genotype but not p53 immunohis-tochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 2002;235:493–498.PubMedCrossRefGoogle Scholar
  7. 7.
    Kandioler-Eckersberger D, Kappel S, Mittlbock M, et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:744–750.PubMedCrossRefGoogle Scholar
  8. 8.
    Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50–56.PubMedGoogle Scholar
  9. 9.
    Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. Endocr Relat Cancer 1999;6:51–59.PubMedCrossRefGoogle Scholar
  10. 10.
    Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155–2162.PubMedGoogle Scholar
  11. 11.
    Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505–2512.PubMedGoogle Scholar
  12. 12.
    Clahsen PC, van de Velde CJ, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998;16:470–479.PubMedGoogle Scholar
  13. 13.
    Andersen PS, Jespersgaard C, Vuust J, Christiansen M, Larsen LA. Capillary electrophoresis-based single strand DNA conformation analysis in high-throughput mutation screening. Hum Mutat 2003;21:455–465.PubMedCrossRefGoogle Scholar
  14. 14.
    Iacopetta B, Elsaleh H, Grieu F, Joseph D, Sterrett G, Robbins P. Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based poly-merase chain reaction and single strand conformation polymorphism. Diagn Mol Pathol 2000;9:20–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Bosserhoff AK, Buettner R, Hellerbrand C. Use of capillary electrophoresis for high throughput screening in biomedical applications. A minireview. Comb Chem High Throughput Screen 2000;3:455–466.PubMedGoogle Scholar
  16. 16.
    Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998;52:79–98.PubMedCrossRefGoogle Scholar
  17. 17.
    Lu ML, Wikman F, Orntoft TF, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002;8:171–179.PubMedGoogle Scholar
  18. 18.
    Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159:2249–2256.PubMedGoogle Scholar
  19. 19.
    Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173–182.PubMedCrossRefGoogle Scholar
  20. 20.
    Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A, Soares F. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol 2003;14:428–432.PubMedCrossRefGoogle Scholar
  21. 21.
    Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997;3:593–600.PubMedGoogle Scholar
  22. 22.
    Formenti SC, Dunnington G, Uzieli B, et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 1997;39:1059–1068.PubMedCrossRefGoogle Scholar
  23. 23.
    Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029–1034.PubMedCrossRefGoogle Scholar
  24. 24.
    Hartmann A, Blaszyk H, Kovach JS, Sommer SS. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 1997;13:27–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Masood S. Assessment of prognostic factors in breast fine-needle aspirates. Am J Clin Pathol 2000;113:S84–S96.PubMedGoogle Scholar
  26. 26.
    Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 2000;6:443–451.PubMedCrossRefGoogle Scholar
  27. 27.
    Chene P. The role of tetramerization in p53 function. Oncogene 2001;20:2611–2617.PubMedCrossRefGoogle Scholar
  28. 28.
    Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811–814.PubMedCrossRefGoogle Scholar
  29. 29.
    Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999;55:28–37.PubMedCrossRefGoogle Scholar
  30. 30.
    Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807–810.PubMedCrossRefGoogle Scholar
  31. 31.
    Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539–542.PubMedCrossRefGoogle Scholar
  32. 32.
    Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002;9:183–195.PubMedCrossRefGoogle Scholar
  33. 33.
    Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophos-phamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412–3417.PubMedGoogle Scholar
  34. 34.
    Rakovitch E, Mellado W, Hall EJ, Pandita TK, Sawant S, Geard CR. Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation. Int J Radiat Oncol Biol Phys 1999;44:1119–1124.PubMedCrossRefGoogle Scholar
  35. 35.
    Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334–2356.PubMedGoogle Scholar
  36. 36.
    Hayes DF. Designing tumor marker studies: will the results provide clinically useful information. Arch Pathol Lab Med 2000;124:952–954.PubMedGoogle Scholar
  37. 37.
    Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887–1892.PubMedCrossRefGoogle Scholar
  38. 38.
    Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003;88:406–412.PubMedCrossRefGoogle Scholar
  39. 39.
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483–2493.PubMedGoogle Scholar
  40. 40.
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–2685.PubMedGoogle Scholar
  41. 41.
    van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224–4237.PubMedGoogle Scholar
  42. 42.
    Stearns V, Singh B, Tsangaris T, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003;9:124–133.PubMedGoogle Scholar
  43. 43.
    Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058–3063.PubMedGoogle Scholar
  44. 44.
    Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002;29:231–245.PubMedCrossRefGoogle Scholar
  45. 45.
    Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996;93:1093–1096.PubMedCrossRefGoogle Scholar
  46. 46.
    Blaszyk H, Hartmann A, Cunningham JM, et al. A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer 2000;89:32–38.PubMedCrossRefGoogle Scholar
  47. 47.
    Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52:227–237.PubMedCrossRefGoogle Scholar
  48. 48.
    Beenken SW, Grizzle WE, Crowe DR, et al. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 2001;233:630–638.PubMedCrossRefGoogle Scholar
  49. 49.
    Elkhuizen PH, van Slooten HJ, Clahsen PC, et al. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol 2000;18:1075–1083.PubMedGoogle Scholar
  50. 50.
    Degeorges A, de Roquancourt A, Extra JM, et al. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat 1998;47:47–55.PubMedCrossRefGoogle Scholar
  51. 51.
    Rahko E, Blanco G, Soini Y, Bloigu R, Jukkola A. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 2002;39:447–453.CrossRefGoogle Scholar
  52. 52.
    Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346–1360.PubMedCrossRefGoogle Scholar
  53. 53.
    Takahashi M, Tonoki H, Tada M, et al. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 2000;89:92–99.PubMedCrossRefGoogle Scholar
  54. 54.
    Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002;1:289–298.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  • Daniela Kandioler
    • 1
  • Raimund Jakesz
    • 1
  1. 1.The Department of SurgeryUniversity of Vienna Medical SchoolViennaAustria

Personalised recommendations